LYEL
Lyell Immunopharma, Inc.LYL797 modulates Not explicitly stated in provided data (likely ROR1 based on context of solid tumor CAR T program, but not confirmed in filing) to treat Solid tumors including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian cancer, and endometrial cancer.
moa:CAR T cell therapy for solid tumors - autologous T cells engineered to target tumor-associated antigens
Phase 1, non-randomized, single-arm study in adults with various advanced/metastatic solid tumors. Enrollment of 57 patients. Evaluating safety (DLTs), anti-tumor activity (ORR by RECIST 1.1), duration of response, PFS, OS, and pharmacokinetic parameters including Cmax, Tmax, AUC, and CAR T cell persistence in peripheral blood.
primary endpoint:Evaluate incidence of dose-limiting toxicities (DLTs) up to 28 days
Not determinable from provided data - no business section text with company claims provided
- TRIAL TERMINATED - Phase 1 trial status is TERMINATED, suggesting potential safety or efficacy concerns
- Target and MOA details not explicitly stated in provided data - requires inference from trial design (CAR T endpoints)
- Incomplete data package - business section text with company claims not provided, only clinical trial metadata available
- Unable to verify claimed differentiation or stated risks without full SEC filing text
- Not explicitly provided in the clinical trial data excerpt - would require business section text
- Not determinable - business section with pipeline milestones not provided